S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Jeff Fager and Brock Greene Host 14th Annual Oligo Nation Masters

On September 14, 2026, the Country Club of New Canaan will host the 14th Annual Oligo Nation Masters, a golf tournament and dinner aimed at securing funding for oligodendroglioma research. The event serves as a critical push to accelerate treatment options for a rare brain cancer lacking new therapeutic breakthroughs.

Jeff Fager and Brock Greene Host 14th Annual Oligo Nation Masters
Photo: Bio & News

Former CBS News executive Jeff Fager joins organization founder Brock Greene to lead this year’s initiative, themed "Driving Research. Accelerating a Cure." The day kicks off at 11:30 a.m. with a tournament at the Country Club of New Canaan, concluding with an evening reception at the Fager residence. The event draws attention to a medical field that has seen no new approved treatments in two decades.

Since its 2014 inception, Oligo Nation has focused on bridging the funding gap for this specific form of brain cancer, which often receives less attention than more common tumor types. Fager, who serves as the nonprofit’s board chairman, emphasized the importance of community involvement, noting that the evening dinner remains a central opportunity for non-golfers to support the cause. Proceeds from the event are directed toward clinical research partnerships designed to move scientific discoveries into trials. Interested participants can find tickets and sponsorship details at the organization's official website.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!